Development of small molecules to target the IgE:FcεRI protein-protein interaction in allergies

Future Medicinal Chemistry

Volumn 5, Issue 12, 2013, Pages 1423-1435

  Smith, Lucy D ^a   Leatherbarrow, Robin J ^a   Spivey, Alan C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYRIN; ANTIHISTAMINIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; CYCLOPEPTIDE; DEXTRO PROTEIN A MIMETIC PEPTIDE; FLUORESCEIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E FC EPSILON RI; IMMUNOGLOBULIN E RECEPTOR; NATURAL PRODUCT; OMALIZUMAB; PEPTIDE; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ALLERGY; ASTHMA; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DISEASE SEVERITY; DRUG BINDING SITE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SUBSTRATE COMPLEX; HAY FEVER; HUMAN; MOLECULE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SURFACE PLASMON RESONANCE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84881517741     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.112     Document Type: Review

References (81)

1. Gupta R, Sheikh A, Strachan DP, Anderson HR. Burden of allergic disease in the UK: secondary analyses of national databases. Clin. Exp. Allergy 34(4), 520-526 (2004).
2. Eder W, Ege MJ, Von Mutius E. Current concepts: the asthma epidemic. N. Engl. J. Med. 355(21), 2226-2235 (2006).
3. Chang TW. The pharmacological basis of anti-IgE therapy. Nat. Biotechnol. 18(2), 157-162 (2000).
4. Gould HJ, Sutton BJ, Beavil AJ et al. The biology of IgE and the basis of allergic disease. Annu. Rev. Immunol. 21, 579-628 (2003).
5. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat. Rev. Immunol. 8(3), 205-217 (2008).
6. Mincarini M, Pasquali M, Cosentino C et al. Antihistamines in the treatment of bronchial asthma. Present knowledge and future perspectives. Pulm. Pharmacol. Ther. 14(4), 267-276 (2001).
7. Raphael GD, Angello JT, Wu MM, Druce HA. Efficacy of diphenhydramine vs desloratadine and placebo in patients with moderate-to-severe seasonal allergic rhinitis. Ann. Allerg. Asthma Im. 96(4), 606-614 (2006).
8. Cazzola M, Segreti A, Matera MG. Novel bronchodilators in asthma. Curr. Opin. Pulm. Med. 16(1), 6-12 (2010).
9. Stoloff SW, Kelly HW. Updates on the use of inhaled corticosteroids in asthma. Curr. Opin. Allergy Clin. Immunol. 11(4), 337-344 (2011).
10. Holgate ST, Chuchalin AG, Hebert J et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allergy 34(4), 632-638 (2004).
11. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J. Allergy Clin. Immunol. 115(3), 459-465 (2005).
12. Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P. The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update. Resp. Med. 103(8), 1098-1113 (2009).
13. Garman SC, Wurzburg BA, Tarchevskaya SS, Kinet JP, Jardetzky TS. Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilon RI alpha. Nature 406(6793), 259-266 (2000).
14. Wan T, Beavil RL, Fabiane SM et al. The crystal structure of IgE Fc reveals an asymmetrically bent conformation. Nat. Immunol. 3(7), 681-686 (2002).
15. Garman SC, Sechi S, Kinet JP, Jardetzky TS. The analysis of the human high affinity IgE receptor Fc epsilon RI alpha from multiple crystal forms. J. Mol. Biol. 311(5), 1049-1062 (2001).
16. Henry AJ, Cook JPD, Mcdonnell JM et al. Participation of the N-terminal region of C epsilon 3 in the binding of human IgE to its high-affinity receptor Fc epsilon RI. Biochemistry 36(50), 15568-15578 (1997).
17. Cook JPD, Henry AJ, Mcdonnell JM, Owens RJ, Sutton BJ, Gould HJ. Identification of contact residues in the IgE binding site of human Fc epsilon RI alpha. Biochemistry 36(50), 15579-15588 (1997).
18. Sayers I, Cain SA, Swan JRM et al. Amino acid residues that influence Fc epsilon RI-mediated effector functions of human immunoglobulin E. Biochemistry 37(46), 16152-16164 (1998).
19. Sayers I, Helm BA. The structural basis of human IgE-Fc receptor interactions. Clin. Exp. Allergy 29(5), 585-594 (1999).
20. Holdom MD, Davies AM, Nettleship JE et al. Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor Fc epsilon RI. Nat. Struct. Mol. Biol. 18(5), 571-576 (2011).
21. Dhaliwal B, Yuan DP, Pang MOY et al. Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor Fc epsilon RI. Proc. Natl Acad. Sci. USA 109(31), 12686-12691 (2012).
22. Borthakur S, Hibbert RG, Pang MOY et al. Mapping of the CD23 binding site on immunoglobulin E (IgE) and allosteric control of the IgE-Fc epsilon RI interaction. J. Biol. Chem. 287(37), 31457-31461 (2012).
23. Wurzburg BA, Jardetzky TS. Conformational flexibility in immunoglobulin E-Fc(3-4) revealed in multiple crystal forms. J. Mol. Biol. 393(1), 176-190 (2009).
24. Wurzburg BA, Kim B, Tarchevskaya SS, Eggel A, Vogel M, Jardetzky TS. An engineered disulfide bond reversibly traps the IgE-Fc(3-4) in a closed, nonreceptor binding conformation. J. Biol. Chem. 287(43), 36251-36257 (2012).
25. Zinzalla G, Thurston DE. Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. Future Med. Chem. 1(1), 65-93 (2009).
26. Buchwald P. Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations. IUBMB Life 62(10), 724-731 (2010).
27. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3(4), 301-317 (2004).
28. Wells JA, Mcclendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450(7172), 1001-1009 (2007).
29. Yin H, Hamilton AD. Strategies for targeting protein-protein interactions with synthetic agents. Angew. Chem. Int. Ed. Engl. 44(27), 4130-4163 (2005).
30. Wilson AJ. Inhibition of protein-protein interactions using designed molecules. Chem. Soc. Rev. 38(12), 3289-3300 (2009).
31. Hamburger RN. Peptide inhibition of Prausnitz-Kustner reaction. Science 189(4200), 389-390 (1975).
32. Hamburger RN. Inhibition of IgE binding to tissure culture cells and leukocytes by pentapeptide. Immunology 38(4), 781-787 (1979).
33. Stanworth DR, Humphrey JH, Bennich H, Johansson SGO. Inhibition of Prausnitz-Kustner reaction by proteolytic cleavage fragments of a human myeloma protein of immunoglobulin class E. Lancet 292(7558), 17-18 (1968).
34. Burt DS, Stanworth DR. Inhibition of binding of rat IgE to rat mast cells by synthetic IgE peptides. Eur. J. Immunol. 17(3), 437-440 (1987).
35. Stanworth DR, Jones VM, Lewin IV, Nayyar S. Allergy treatment with a peptide vaccine. Lancet 336(8726), 1279-1281 (1990).
36. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23(1-3), 3-25 (1997).
37. Stigers KD, Soth MJ, Nowick JS. Designed molecules that fold to mimic protein secondary structures. Curr. Opin. Chem. Biol. 3(6), 714-723 (1999).
38. Mcdonnell JM, Beavil AJ, Mackay GA et al. Structure based design and characterization of peptides that inhibit IgE binding to its high-affinity receptor. Nat. Struct. Biol. 3(5), 419-426 (1996).
39. Kotha S, Lahin K. Application of the Suzuki-Miyaura cross-coupling reaction for the modification of phenylalanine peptides. Biopolymers 69(4), 517-528 (2003).
40. Helm BA, Spivey AC, Padlan EA. Peptide blocking of IgE/receptor interaction: possibilities and pitfalls. Allergy 52(12), 1155-1169 (1997).
41. Spivey AC, Mckendrick JE, Srikaran R, Helm BA. Solid-Phase synthesis of an A-B loop mimetic of the Ce3 domain of human IgE: macrocyclization by sonogashira coupling. J. Org. Chem. 68(5), 1843-1851 (2003).
42. Offermann DA, Mckendrick JE, Sejberg JJP et al. Synthesis and incorporation into cyclic peptides of tolan amino acids and their hydrogenated congeners: construction of an array of A-B-loop mimetics of the c epsilon 3 domain of human IgE. J. Org. Chem. 77(7), 3197-3214 (2012).
43. Mcdonnell JM, Beavil AJ, Mackay GA et al. Structure-based design of peptides that inhibit IgE binding to its high-affinity receptor Fc epsilon RI. Biochem. Soc. Trans. 25(2), 387-392 (1997).
44. Mcdonnell JM, Fushman D, Cahill SM, Sutton BJ, Cowburn D. Solution structures of Fc epsilon RI alpha-chain mimics: a beta-hairpin peptide and its retroenantiomer. J. Am. Chem. Soc. 119(23), 5321-5328 (1997).
45. Danho W, Makofske R, Swistok J et al. High affinity IgE-receptor-a- subunit-derived peptides as antagonists of human IgE binding. Peptides Am. Symp. 15, 539-540 (1997).
46. Sandomenico A, Monti SM, Marasco D et al. IgE-binding properties and selectivity of peptide mimics of the Fc epsilon RI binding site. Mol. Immunol. 46(16), 3300-3309 (2009).
47. Sandomenico A, Monti SM, Palumbo R, Ruvo M. A new FceRI receptor-mimetic peptide (PepE) that blocks IgE binding to its high affinity receptor and prevents mediator release from RBL 2H3 cells. J. Pept. Res. 17(9), 604-609 (2011).
48. Nakamura GR, Starovasnik MA, Reynolds ME, Lowman HB. A novel family of hairpin peptides that inhibit IgE activity by binding to the high-affinity IgE receptor. Biochemistry 40(33), 9828-9835 (2001).
49. Nakamura GR, Reynolds ME, Chen YM, Starovasnik MA, Lowman HB. Stable 'zeta' peptides that act as potent antagonists of the high-affinity IgE receptor. Proc. Natl Acad. Sci. USA 99(3), 1303-1308 (2002).
50. Stamos J, Eigenbrot C, Nakamura GR et al. Convergent recognition of the IgE binding site on the high-affinity IgE receptor. Structure 12(7), 1289-1301 (2004).
51. Fassina G, Verdoliva A, Odierna MR, Ruvo M, Cassini G. Protein a mimetic peptide ligand for affinity purification of antibodies. J. Mol. Recognit. 9(5-6), 564-569 (1996).
52. Fassina G, Verdoliva A, Palombo G, Ruvo M, Cassani G. Immunoglobulin specificity of TG19318: a novel synthetic ligand for antibody affinity purification. J. Mol. Recognit. 11(1-6), 128-133 (1998).
53. Fassina G, Ruvo M, Palombo G, Verdoliva A, Marino M. Novel ligands for the affinity-chromatographic purification of antibodies. J. Biochem. Biophys. Methods 49(1-3), 481-490 (2001).
54. Palombo G, De Falco S, Tortora M, Cassani G, Fassina G. A synthetic ligand for IgA affinity purification. J. Mol. Recognit. 11(1-6), 243-246 (1998).
55. Palombo G, Rossi M, Cassani G, Fassina G. Affinity purification of mouse monoclonal IgE using a protein A mimetic ligand (TG19318) immobilized on solid supports. J. Mol. Recognit. 11(1-6), 247-249 (1998).
56. Palombo G, Verdoliva A, Fassina G. Affinity purification of immunoglobulin M using a novel synthetic ligand. J. Chromatogr. B 715(1), 137-145 (1998).
57. Verdoliva A, Basile G, Fassina G. Affinity purification of immunoglobulins from chicken egg yolk using a new synthetic ligand. J. Chromatogr. B 749(2), 233-242 (2000).
58. Verdoliva A, Pannone F, Rossi M, Catello S, Manfredi V. Affinity purification of polyclonal antibodies using a new all-D synthetic peptide ligand: comparison with protein A and protein G. J. Immunol. Methods 271(1-2), 77-88 (2002).
59. Marino M, Ruvo M, De Falco S, Fassina G. Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide. Nat. Biotechnol. 18(7), 735-739 (2000).
60. Marino M, Rossi M, Ruvo M, Fassina G. Novel molecular targets for systemic lupus erythematosus. Curr. Drug Targets 3(3), 223-228 (2002).
61. Rossi M, Ruvo M, Marasco D, Colombo M, Cassani G, Verdoliva A. Anti-allergic properties of a new all-D synthetic immunoglobulin-binding peptide. Mol. Immunol. 45(1), 226-234 (2008).
62. Ratcliffe NA, Mello CB, Garcia ES, Butt TM, Azambuja P. Insect natural products and processes: new treatments for human disease. Insect Biochem. Mol. Biol. 41(10), 747-769 (2011).
63. Buku A, Maulik G, Hook WA. Bioactivities and secondary structure of mast cell degranulating (MCD) peptide analogs. Peptides 19(1), 1-5 (1998).
64. Buku A. Mast cell degranulating (MCD) peptide: a prototypic peptide in allergy and inflammation. Peptides 20(3), 415-420 (1999).
65. Buku A, Price JA. Further studies on the structural requirements for mast cell degranulating (MCD) peptide-mediated histamine release. Peptides 22(12), 1987-1991 (2001).
66. Buku A, Price JA, Mendlowitz M, Masur S. Mast cell degranulating peptide binds to RBL- 2H3 mast cell receptors and inhibits IgE binding. Peptides 22(12), 1993-1998 (2001).
67. Buku A, Mendlowitz M, Condie BA, Price JA. Histamine-releasing activity and binding to the Fc epsilon RI alpha human mast cell receptor subunit of mast cell degranulating peptide analogues with alanine substitutions. J. Med. Chem. 46(14), 3008-3012 (2003).
68. Buku A, Mendlowitz M, Condie BA, Price JA. Partial alanine scan of mast cell degranulating peptide (MCD): importance of the histidine-and arginine residues. J. Pept. Res. 10(6), 313-317 (2004).
69. Buku A, Condie BA, Price JA, Mezei M. Ala(12) MCD peptide: a lead peptide to inhibitors of immunoglobulin E binding to mast cell receptors. J. Pept. Res. 66(3), 132-137 (2005).
70. Buku A, Keselman I, Lupyan D, Mezei M, Price JA. Effective mast cell degranulating peptide inhibitors of the IgE/Fc epsilon RI receptor interaction. Chem. Biol. Drug Des. 72(2), 133-139 (2008).
71. Singh SB, Jayasuriya H, Zink DL, Polishook JD, Dombrowski AW, Zweerink H. Aspercyclide A-C, three novel fungal metabolites from Aspergillus sp as inhibitors of high-affinity IgE receptor. Tetrahedron Lett. 45(41), 7605-7608 (2004).
72. Pospisil J, Muller C, Fürstner A. Total synthesis of the aspercyclides. Chem. Eur. J. 15(24), 5956-5968 (2009).
73. Yoshino T, Sato I, Hirama M. Total Synthesis of aspercyclides A and B via intramolecular oxidative diaryl ether formation. Org. Lett. 14(16), 4290-4292 (2012).
74. Carr JL, Offermann DA, Holdom MD et al. Total synthesis of (+/-)-aspercyclide A and its C19 methyl ether. Chem. Commun. 46(11), 1824-1826 (2010).
75. Carr JL, Sejberg JJP, Saab F et al. Synthesis of the C19 methyl ether of aspercyclide A via germyl-Stille macrocyclisation and ELISA evaluation of both enantiomers following optical resolution. Org. Biomol. Chem. 9(19), 6814-6824 (2011).
76. Eggel A, Baumann MJ, Amstutz P, Stadler BM, Vogel M. DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage. J. Mol. Biol. 393(3), 598-607 (2009).
77. Baumann MJ, Eggel A, Amstutz P, Stadler BM, Vogel M. DARPins against a functional IgE epitope. Immunol. Lett. 133(2), 78-84 (2010).
78. Eggel A, Buschor P, Baumann MJ, Amstutz P, Stadler BM, Vogel M. Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin-Fc fusion protein. Allergy 66(7), 961-968 (2011).
79. Kim B, Eggel A, Tarchevskaya SS, Vogel M, Prinz H, Jardetzky TS. Accelerated disassembly of IgE-receptor complexes by a disruptive macromolecular inhibitor. Nature 491(7425), 613-617 (2012).
80. Wiegand T, Williams P, Dreskin S, Jouvin M, Kinet J, Tasset D. High-affinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I. J. Immunol. 157(1), 221-230 (1996).
81. Kim B, Tarchevskaya SS, Eggel A, Vogel M, Jardetzky TS. A time-resolved fluorescence resonance energy transfer assay suitable for high-throughput screening for inhibitors of immunoglobulin E-receptor interactions. Anal. Biochem. 431(2), 84-89 (2012).